» Articles » PMID: 18690953

Adverse Drug Reactions in Hospitals: a Narrative Review

Overview
Journal Curr Drug Saf
Specialty Pharmacology
Date 2008 Aug 12
PMID 18690953
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

The serious nature of adverse drug reactions (ADRs) has been highlighted in a number of instances over the last forty years, the most recent of these being the occurrence of serious thrombotic events with the use of COX-2 inhibitors. ADRs are estimated to be between the 4(th) and 6(th) leading cause of death in the USA, with fatal ADRs occurring in 0.32% of patients. A recent UK study showed that 6.5% of hospital admissions were related to ADRs. ADRs can therefore be regarded as a significant public health and economic problem. There is an urgent need to develop better preventive strategies to reduce the burden of ADRs. Because ADRs can affect any bodily system, can have many different clinical presentations, and are of widely variable severity, prevention will not be easy and will have to be multifactorial in its approach. This paper reviews the epidemiology of ADRs in hospitals and evaluates the research that has been undertaken to date to prevent ADRs.

Citing Articles

Adverse drug reactions and its associated factors among geriatric hospitalized patients at selected comprehensive specialized hospitals of the Amhara Region, Ethiopia: a multicenter prospective cohort study.

Dagnew S, Moges T, Ayele T, Wondm S, Yazie T, Dagnew F BMC Geriatr. 2024; 24(1):955.

PMID: 39550566 PMC: 11568537. DOI: 10.1186/s12877-024-05515-y.


Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.

Wu J, Wu J, Tang B, Wang X, Wei F, Zhang Y Front Pharmacol. 2024; 15:1399172.

PMID: 39309013 PMC: 11412890. DOI: 10.3389/fphar.2024.1399172.


Pharmacogenetic Approach for the Prevention of Rivaroxaban's ADRs: A Systematic Review and Meta-Analysis.

Mardi P, Abbasi B, Shafiee A, Afsharmoghaddam T Genet Res (Camb). 2023; 2023:6105320.

PMID: 37942082 PMC: 10630013. DOI: 10.1155/2023/6105320.


Incidence and Severity of Adverse Drug Reactions in Medical Intensive Care Unit.

Shaikh S, Raut A, Jambhale P, Iyer S, Shah J Curr Drug Saf. 2023; 19(3):332-341.

PMID: 37587829 DOI: 10.2174/1574886318666230816090606.


Individual Pharmacotherapy Management (IPM)-IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy.

Wolf U, Baust H, Neef R, Steinke T Antibiotics (Basel). 2022; 11(10).

PMID: 36290039 PMC: 9599027. DOI: 10.3390/antibiotics11101381.